The definitive guide to insurance agency valuation methods.

Most agency owners receive their first formal exposure to valuation methodology when a buyer makes them an offer. By then they have no framework to evaluate whether the offer is fair — only a price on a piece of paper and a deadline. This Tactical provides the comprehensive overview of all four primary valuation methods used in professional insurance agency M&A, which buyer types prefer each, and what the load-bearing dispute actually looks like in practice.

§ 01 · Why the numbers matterThe $1M gap on a $500K EBITDA agency.

The cost of operating without a defensible valuation is observable. On a $500,000 EBITDA agency: at 5× = $2.5M, at 6× = $3.0M, at 7× = $3.5M. The difference between a weak negotiating position (5×) and a strong one (7×) is $1 million on the same business. That gap comes from having objective, defensible valuation data before engaging any buyer.

Mapped to the canonical bands: 5× sits inside the 4–6× distressed-or-internal band; 7× clears the bottom of the 8–10× market band only with documentation that supports the leap. The same EBITDA produces different bands depending on what the seller can prove.

§ 02 · The four primary valuation methodsWhat each one actually does.

Method 1 — Income Approach (DCF).

Projects future cash flows and discounts to present value. Formula: Enterprise Value = (Projected Year 1 Cash Flow × (1 + Growth Rate)^Years) ÷ Discount Rate. Used by strategic buyers, PE firms, and any situation where growth potential is a key value driver. Strengths: reflects future earning power; captures growth trajectory. Weaknesses: highly sensitive to assumptions; can over- or under-value depending on projection quality.

Method 2 — Market-Based Approach (Comparable Transactions).

Looks at what similar agencies recently sold for and applies those benchmarks. Used in virtually all strategic-buyer valuations, by banks and lenders, and in negotiations between sophisticated parties. Strengths: based on real market transactions; easy to understand and defend. Weaknesses: requires access to good comparable data (often confidential); market conditions change.

Method 3 — EBITDA Multiple Approach.

The gold standard for professional M&A. Formula: Valuation = Normalized EBITDA × Multiple. Used by strategic buyers (most common), PE acquisitions, and loan valuations. Strengths: simple, transparent, universally understood; can be supported by comparable data. Weaknesses: multiple varies widely; heavily dependent on accurate Normalized EBITDA.

Method 4 — Asset-Based Approach.

Values the agency by adding tangible and intangible assets. For insurance agencies, intangible assets — goodwill and client relationships — represent 80–90% of value, yet this method struggles to capture them without income-approach reference. Used in tax valuations for succession planning and estate planning; rarely in actual M&A transactions. Strengths: comprehensive, useful for tax planning. Weaknesses: results in undervaluations; fails to capture earning power; almost never what buyers will pay.

§ 03 · Which method which buyer prefersThe taxonomy.

Strategic Buyers (consolidators): EBITDA Multiple or Market Comps primary; DCF secondary. Private Equity / Financial Sponsors: Normalized EBITDA + DCF primary; market validation secondary. Smaller Buyers / Roll-Up Operators: EBITDA Multiple primary; sometimes aggressive comps. Banks and Lenders: Market Comps or EBITDA Multiple.

Smaller buyers often undervalue agencies because they lack professional transaction data. This is where having an independent valuation becomes critical — the smaller-buyer's data gap becomes the seller's leverage gap unless the seller closes it themselves.

§ 04 · The Normalized EBITDA disputeThe hidden issue that outweighs the multiple.

More valuation disputes come from disagreements about Normalized EBITDA than from disagreements about the multiple. Three common disputes show up in nearly every transaction.

"You pay yourself too much." Owner earns $300K; buyer argues market rate for a replacement GM is $150K and normalizes EBITDA down to $150K, offering a lower price. "That was a one-time expense." $50K legal settlement last year — is it recurring or not? "That revenue isn't sustainable." 20% from a single new client — is that the baseline expectation, or is the agency about to lose a key client?

Protection: get Normalized EBITDA reviewed by a CPA before valuation. Know which adjustments are defensible — and which won't survive buyer scrutiny.

§ 05 · Valuation in practiceAn $800K range on the same agency.

Agency with $1.5M revenue, $150K stated EBITDA, $100K excess owner salary, $20K one-time consulting fee. Normalized EBITDA = $150K + $100K + $20K + (allowance) = approximately $320K.

DCF approach: $320K × 1.05 growth over 5 years, discounted at 12% → approximately $1.3M–$1.5M. Market-Based approach: comparable agencies at 5.8× EBITDA → approximately $1.86M. EBITDA Multiple approach: 6.5× (high quality) = $2.08M; 5.5× (average) = $1.76M; 4.5× (below average) = $1.44M.

An $800K+ range on the same agency, based on method selection and quality assessment alone. This is exactly why independent valuation before negotiations is critical — and why the seller who walks in with one number gets the bottom of the range.

Mapped to the canonical bands: 4.5× sits in the 4–6× distressed band; 5.5–5.8× sits at the top of the same band; 6.5× sits just below the 8–10× market band. The agency's quality profile — retention, growth, concentration, documentation — is what determines which band the multiple actually clears.

◆